Dolutegravir/ abacavir /lamivudine

Extended indication	Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg.
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Dolutegravir/ abacavir /lamivudine
Domain	Infectious diseases
Reason of inclusion	Indication extension
Main indication	Viral infections other
Extended indication	Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg.
Manufacturer	ViiV

Submission date	October 2023
Expected Registration	August 2024
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.